JYNT — The Joint Corp.

Summary of JYNT Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased 6% year-over-year to $13.4 million, primarily due to a greater number of franchise clinics.
• Adjusted EBITDA: Grew 36% to $3.3 million, reflecting cost management efforts despite a 1.5% decline in system-wide sales and negative comp sales of 2%.
• Net Income: Consolidated net income was $855,000, a significant improvement from a net loss of $3.2 million in Q3 2024.
• Cash Position: Unrestricted cash and cash equivalents stood at $29.7 million, up from $25.1 million year-over-year.
• Stock Repurchase: $5 million of stock repurchased in Q3, with an additional $12 million authorized.

2. Strategic Updates and Business Highlights

• Marketing Initiatives: Shifted focus to pain relief in brand marketing to attract new patients, supported by a national campaign and enhanced digital marketing efforts.
• Refranchising Strategy: An initial agreement to sell 45 corporate clinics in Southern California for $4.5 million. Ongoing negotiations for 33 additional clinics.
• Patient Experience Enhancements: Launched a new mobile app with features aimed at improving patient engagement, achieving 178,000 downloads and an 18% adoption rate among new patients.
• Dynamic Revenue Management: Introduced a new pricing pilot for wellness plans to optimize revenue, testing three different price increase tiers across various demographics.

3. Forward Guidance and Outlook

• Revised Full-Year Guidance: System-wide sales expected between $530 million and $534 million (down from previous guidance of $530 million to $550 million). Comp sales projected to be negative 1% to flat.
• Adjusted EBITDA: Maintained guidance of $10.8 million to $11.8 million.
• 2026 Outlook: Anticipates improved profitability in 2026 due to ongoing refranchising and cost structure realignment.

4. Bad News, Challenges, or Points of Concern

• Declining Metrics: System-wide sales down 1.5% and comp sales down 2%, attributed to lower new patient counts.
• Macroeconomic Headwinds: Challenges in refranchising due to lender dynamics affecting the timing of asset sales.
• Competitive Pressures: Facing tough comparisons with prior year performance, particularly in Q4 where comps were up 4% last year.

5. Notable Q&A Insights

• Refranchising Timeline: Management indicated that while the exact timing for completing refranchising is uncertain due to macroeconomic factors, they are confident in making progress.
• Pricing Strategy: Management is cautious about raising prices amid declining comps, emphasizing a careful approach to ensure patient sensitivity is considered.
• New Clinic Performance: Improvements in breakeven timing for new clinics due to enhanced preopening protocols, with a focus on generating leads before opening.
• App Engagement: While initial feedback on the app is positive, it is too early to provide metrics on its impact on scheduling or patient retention.

Overall, while The Joint Corporation is experiencing some challenges with comp sales and refranchising timelines, strategic initiatives in marketing, technology, and pricing are aimed at driving future growth and profitability.